ArticleEuropean journal of nuclear medicine and molecular imaging2020
The radiosensitizer Onalespib increases complete remission in
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- [EJNMMI research · 2026Article
- Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.The Journal of clinical endocrinology and metabolism · 2026Article
- Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.EJNMMI research · 2025Article
- Review
- Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy.Frontiers in oncology · 2025Article
- Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Estimating the distribution of parameters in differential equations with repeated cross-sectional data.PLoS computational biology · 2024Article
- Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers.Cancer research communications · 2024Article
- Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers.bioRxiv : the preprint server for biology · 2024Article
- p53 stabilisation potentiates [European journal of nuclear medicine and molecular imaging · 2024Article
- Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics · 2024Review
- Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.Scientific reports · 2023Article
- HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients.Translational lung cancer research · 2023Article
- Enhanced Therapeutic Effects ofCancers · 2023Article
- Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.International journal of nanomedicine · 2023Review
- Review
- Radiotheranostics in oncology: current challenges and emerging opportunities.Nature reviews. Clinical oncology · 2022Review
- Peptide Receptor Radionuclide Therapy with [Cancers · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose
methods
resultsBiodistribution and autoradiography confirmed the SSTR-selective tumor uptake of
conclusionTreatment with Onalespib potentiated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.